Big Data as a Service Market Report 2022-2027, Industry Share, Size, Growth, Trends and Opportunities
Big Data as a Service Market Report 2022-2027, Industry Share, Size, Growth, Trends and Opportunities
- Get link
- Other Apps
According to the latest report by IMARC Group, titled “Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the biosimilar market in Europe reached a value of US$ 5,341 Million in 2020. Biosimilars are biological drugs which are similar to approved branded biologics in terms of their safety, efficacy, structure and immunogenicity profile. They are manufactured and approved in accordance with the stringent laws of the European Medicines Agency (EMA). Over the years, there has been a rise in the prevalence of chronic diseases such as obesity, stroke, cancer, seizure and heart attacks owing to the increasing aging population. For instance, as per one of the recent reports by WHO, cancer has emerged as one of the major causes of death and morbidity in the region.
Request
for a PDF sample of this report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample
We
are regularly tracking the direct effect of COVID-19 on the market, along with
the indirect influence of associated industries. These observations will be
integrated into the report.
Market
Trends:
As
patients have limited access to biologics on account of their high prices,
there is a huge demand for biosimilars in the region. Biosimilars are
relatively less expensive as they do not require extensive investment for
research and development activities and marketing, which saves time as well as
money of the manufacturers. This has further assisted in reducing the overall
cost of treating chronic diseases. Moreover, the increasing awareness
among patients about the safety and efficiency of biosimilars is creating a
positive outlook for the market growth. In line with this, the EMA and the
European Commission are working to improve the understanding of biosimilars
across the European Union. Looking forward, IMARC
Group expects the market to grow at a CAGR of 22.1% during 2021-2026.
Market
Summary:
·
Based
on the molecule, the market has been segmented into infliximab, insulin
glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab and
follitropin alfa. Currently, infliximab dominates the market, holding the
largest share as it is used in the treatment of numerous inflammatory disorders
like plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
·
On
the basis of the manufacturing type, in-house manufacturing represents the
largest segment, followed by contract manufacturing. In-house manufacturing
enables companies to monitor every step of the biosimilar manufacturing
process.
·
Country-wise,
the market has been classified into Italy, Germany, France, the United Kingdom,
Spain and Rest of Europe. Amongst these, Italy is the leading market,
accounting for the majority of the total market share due to healthcare cost
containment measures adopted in the country.
·
The
competitive landscape of the market has also been examined with some of the key
players being Novartis, Pfizer, Teva, Celltrion, Merck Sharp & Dohme,
Samsung Bioepis, Eli Lilly, Accord Healthcare Ltd., Amgen, Boehringer
Ingelheim, Hexal Ag, Apotex, Stada Arzneimittel Ag, Ratiopharm and Mylan.
Some of the leading players operating in
the European biosimilars market include:
Breakup
by Country:
·
Italy
·
Germany
·
United
Kingdom
·
France
·
Spain
·
Others
Breakup
by Molecule
·
Infliximab
·
Insulin
Glargine
·
Epoetin
Alfa
·
Etanercept
·
Filgrastim
·
Somatropin
·
Rituximab
·
Follitropin
Alfa
·
Adalimumab
Breakup
by Indication
·
Auto-Immune
Diseases
·
Blood
Disorder
·
Diabetes
·
Oncology
·
Growth
Deficiency
·
Female
Infertility
Breakup
by Manufacturing Type
·
In-house
Manufacturing
·
Contract
Manufacturing
Ask Analyst for Customization and
Explore full report with TOC & List of Figures: https://www.imarcgroup.com/europe-biosimilar-market
We are updating our reports, If you want latest primary and secondary
data (2021-2026) with Cost Module, Business Strategy, Distribution Channel,
etc. Click request free sample report, published report will be delivered to
you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
If you need specific
information that is not currently within the scope of the report, we will
provide it to you as a part of the customization.
Related Reports by IMARC Group:
Indonesia prepaid cards market: Industry Trends, Size, Growth, Opportunity and Forecast 2021-2026
North America Frozen Seafood Market: Industry Trends, Size, Growth, Opportunity and Forecast 2021-2026
GCC Fresh Milk Market: Industry Trends, Size, Growth, Opportunity and Forecast 2021-2026
Southeast Asia Fire Sprinkler Heads Market: Industry Trends, Size, Growth, Opportunity and Forecast 2021-2026
Heavy-Duty Automotive Aftermarket Market: Industry Trends,
Size, Growth, Opportunity and Forecast 2021-2026
IMARC Group is a leading market research company
that offers management strategy and market research worldwide. We partner with
clients in all sectors and regions to identify their highest-value
opportunities, address their most critical challenges, and transform their
businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801
USA - Wyoming
Email:
Sales@imarcgroup.com
Tel No:(D) +91 120
433 0800
Americas: - +1 631
791 1145 | Africa and Europe: - +44-702-409-7331 | Asia: +91-120-433-0800,
+91-120-433-0800
Comments
Post a Comment